ArticleBrain, behavior, & immunity - health2025
Detection of autoantibodies against Interferon Type I in patients with autochthonous West Nile Virus encephalitis.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Endemic progression of autochthonous West Nile virus infections in Europe.European journal of microbiology & immunology · 2026Review
- Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.Journal of human immunity · 2026Article
- Pharmaceutical Strategies for West Nile Virus in Europe, an Underrecognized Cause of Severe Disease and Mortality in Older Adults: From Supportive Care to Antiviral Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
West Nile virus (WNV) is a neurotropic flavivirus that has become a global concern because of its rapid geographical spread and its capacity to cause severe disease in humans. Although often asymptomatic, infection can lead to life-threatening neuroinvasive disease (WNND) in a small percentage of cases, particularly among elderly individuals and individuals with compromised immune responses. We present three cases of autochthonous WNND from Germany from 2023 to 2024, which showcase various neurological manifestations and their correlation with immune responses. Two elderly men developed severe encephalitis symptoms, whereas one patient presented with only mild encephalitis symptoms but severe flaccid paresis. Notably, two patients (Patients One and Two) had neutralizing autoantibodies against interferon-α2 and interferon-ω, along with neutralizing antibodies against interferon-β in Patient One. This may implicate impaired viral immunity and severe disease progression. Complete genome sequencing revealed lineage 2 sequences with high similarity to WNV sequences obtained from other patients, birds, and mosquitoes in Germany. Our report raises concerns about the underdiagnosis of WNV in Germany, where human cases remain underreported despite the presence of endemic infections in animals and competent mosquito vectors. Given the increasing prevalence of WNV in Europe, intensified surveillance and awareness are critical. The variability in clinical presentations and the potential for fatal outcomes underscore the importance of early recognition and individualized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.